For instance, Kite Pharma’s CD19-redirected CAR-T product, brexucabtagene autoleucel, has been FDA-approved for the treatment of certain patients with MCL (as the 3rd line) as well as those with B-ALL (as the 3rd line) [9, 62]. Here, CD19 is linked to acute lymphoblastic leukemia.